H Kuhl

No ORCID on file · 7 papers in corpus
other 2004
Contraception ·doi:10.1016/j.contraception.2003.09.004

Long-cycle regimens with continuous use of oral contraceptives (OCs) for 3 or 6 months followed by a hormone-free interval of 7 days may reduce or prevent cycle-dependent and menses-related complaints. A representative survey carried out wi…

rct 2004
Contraception ·doi:10.1016/j.contraception.2004.03.004

This is the first double-blind, controlled, randomized study comparing the effect of different estrogen components in oral contraceptives (OCs) on hemostasis variables. Four groups of 25 women each were treated for six cycles with monophasi…

rct 2004
Climacteric : the journal of the International Menopause Society ·doi:10.1080/13697130310001651445

OBJECTIVE: Two randomized comparative multicenter studies were conducted to establish the endometrial safety and tolerability of a triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate (E2V/MPA) therapy reg…

rct 2003
Contraception ·doi:10.1016/s0010-7824(03)00006-4

In a double-blind, controlled, randomized, four-arm, bicentric clinical study, the effect of four oral contraceptives (OCs) on thyroid hormone parameters, cortisol, aldosterone, endothelin-1 and angiotensin II was investigated. Four groups …

rct 2002
Contraception ·doi:10.1016/s0010-7824(01)00310-9

In a double-blind, controlled, randomized, four-arm, bicentric clinical study, the effect of four oral contraceptives (OCs) on lipid metabolism was investigated. Four groups composed of 25 volunteers each (mean age 26.1 +/- 4.5 years; body …

review 2001
Therapeutische Umschau. Revue therapeutique ·doi:10.1024/0040-5930.58.9.527

Due to their high oral bioavailability synthetic progestagens are used for therapy, hormone replacement therapy and contraception There are different types of progestogens. There are progesterone derivatives, nortestosterone derivatives (13…

review 1996
Drugs ·doi:10.2165/00003495-199651020-00002

The newer progestogens desogestrel, norgestimate, gestodene, dienogest and nomegestrol share the common property of having weak or no androgenic effects, but there is great variation between agents in their pharmacokinetic properties and ho…